Literature DB >> 1967177

Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1.

M B Zimering1, M L Brandi, D A deGrange, S J Marx, E Streeten, N Katsumata, P R Murphy, Y Sato, H G Friesen, G D Aurbach.   

Abstract

Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen found in a variety of normal and tumor tissues. Basic FGF lacks a classical signal sequence, and it is not clear how it is released from cells. bFGF or bFGF-like activity has not been previously demonstrated in plasma. In an earlier study we showed increased mitogenic activity for parathyroid-derived epithelial and mesenchymal cells in plasma of subjects with familial multiple endocrine neoplasia type 1 (FMEN1). In the present study we examined the growth-promoting activity of normal and FMEN1 plasmas [applied to heparin-Sepharose (HS) columns] in parathyroid-derived cloned endothelial cells. FMEN1 plasma HS-adsorbed activity exceeded normal plasma HS-adsorbed activity in 6 of 8 FMEN1 plasma samples. Peak (FMEN1 plasma) HS-adsorbed activity eluted with 0.1-0.3 M NaCl, was completely neutralized by specific antibodies against bFGF, and had an apparent mol wt of 110 kD. Active fractions from FMEN1 plasma prepared by gel filtration in 7 M urea displayed apparent mol wt of about 14-16 kD and showed increased apparent affinity for HS; recovered activity appeared principally in the 3.0-M NaCl eluate. Using a sensitive two-site immunoradiometric assay for bFGF we found 0.4 ng/mL bFGF-like immunoreactivity in the highly purified 3.0-M NaCl eluate from a HS column to which the active components from gel filtration of FMEN1 plasma in 7 M urea were applied. These results imply that bFGF or closely related factors circulate in FMEN1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967177     DOI: 10.1210/jcem-70-1-149

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Multiple endocrine neoplasia type I: general features and new insights into etiology.

Authors:  M L Brandi
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

2.  Molecular atherectomy for restenosis.

Authors:  W Casscells; D A Lappi; A Baird
Journal:  Trends Cardiovasc Med       Date:  1993 Nov-Dec       Impact factor: 6.677

Review 3.  Cellular models for the analysis of paracrine communications in parathyroid tissue.

Authors:  M L Brandi
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

Review 4.  "Asymptomatic" and symptomatic primary hyperparathyroidism.

Authors:  J A Fischer
Journal:  Clin Investig       Date:  1993-07

5.  Identification of soluble forms of the fibroblast growth factor receptor in blood.

Authors:  A Hanneken; W Ying; N Ling; A Baird
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

6.  Multiple endocrine neoplasia type 1 parathyroid adenoma development over time.

Authors:  Gerard M Doherty; Terry C Lairmore; Mary K DeBenedetti
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

7.  Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor.

Authors:  T D'Adda; A Amorosi; G Bussolati; M L Brandi; C Bordi
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription.

Authors:  I Shimon; A Hüttner; J Said; O M Spirina; S Melmed
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I.

Authors:  M Komatsu; S Tsuchiya; I Matsuyama; S Kaneko; Y Suzuki; N Ito; N Hanamura; T Seki; S Kobayashi; T Kuroda
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

10.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.